Unlocking healthcare with AI

No items found.

September 16, 2021

Additional information

Table of contents

Toc Heading
Toc Heading

Much has been written about the development of artificial intelligence (AI) and its potential to reshape everyday life.

This potential is already being realised in healthcare, with health professionals utilising tools incorporating AI. Among the most exciting uses of AI in healthcare include:

Diagnosis;

Treatment control;

Drug development and discovery; and

Monitoring of infectious disease.

For example, AI techniques can assist professionals in diagnosing breast cancer by learning to identify indications of possible breast cancer in mammograms, or AI techniques can be used to control the administration of insulin to diabetes patients.

A topical example of the power of AI techniques is the identification by BlueDot, a Canadian software firm which uses AI-based algorithms to monitor publicly available data including news reports, of a ‘pneumonia' cluster in the Chinese city of Wuhan on December 31, 2020, over a week before the World Health Organization (WHO) informed the public that the Wuhan outbreak could be a novel coronavirus.

The WHO has since concluded that, had governments and policy makers acted faster, a pandemic of this scale could have been avoided.

AI and patentability

As with many emerging technologies, the pace of development of AI tends to be faster than the development of the laws regulating it.

Over the past few years, there has been an increasing debate over whether existing patent law is fit for AI-based innovations. Some argue that existing patent law is too strict and patents should more easily be granted for AI-based innovation to encourage investment and commercialisation. Others argue that patents should not be granted for AI-based innovation as it has the potential to stifle innovation in a fast-moving field.

Patent Offices around the world are currently investigating what AI-based innovations should and should not be susceptible to patent protection.

Given the ongoing efforts to harmonise patent law throughout the world, these investigations will not be carried out in isolation and we can expect there to be broad conformity in the eventual outcome. Nevertheless, we can also expect there to be differences in the detail.

The rest of this article is available to download as part of our ‘what's next for medtech' whitepaper. Download for free here.

Recent Case Reports

See all Case Reports

Bringing enforcement proceedings while an appeal is still pending risks liability for defendant’s costs

24 September 2026

The Court of Appeal held that setting aside a first-instance decision granting relief subject to recurring penalties generally has retroactive effect. Any penalty fees already paid will be refunded by the Court. The value of proceedings is determined by the interest of the party that brought the action. This is not changed as a result of an appeal. A claimant bringing enforcement proceedings while an appeal is still pending does so at its own risk and may be liable for the defendant’s costs related to the enforcement proceedings.‍

Replacement parts and the value of asserting a narrower claim combination

17 July 2026

The UPC's Düsseldorf Local Division found that Wessper's cartridges indirectly infringed Brita's patent, and that a narrower claim combination can turn a consumable into an essential element.

Preliminary objection on jurisdiction partially successful – UPC clarifies requirements of anchor-defendant jurisdiction for non-UPC territories

25 June 2026

The Hamburg Local Division let Nixu pursue US-based Infoblox in the UPC for Germany, France and Finland, but threw out the UK claim. To reach a non-UPC territory through an anchor defendant, a claimant must plead joint infringement there.